HEB Hemispherx BioPharma Inc.

0  -2%
Previous Close 0.15
Open 0.14
Price To Book 1.81
Market Cap 9019638
Shares 62,290,318
Volume 1,190,569
Short Ratio 0.29
Av. Daily Volume 1,301,642

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL February 4, 2013.

Latest News

  1. Some Hemispherx Biopharma (NYSEMKT:HEB) Shareholders Have Copped A 96% Share Price Wipe Out
  2. Hemispherx Announces the First Participant Received Initial Dosing in Breast Cancer Clinical Trial Using Hemispherx’ Ampligen and Pembrolizumab
  3. Hemispherx Reports 2018 Year-end Financial Results
  4. Hemispherx Biopharma Announces Significant Progress in its Ampligen Pancreatic Cancer Program and Multiple Ampligen+Checkpoint Blockade Immuno-Oncology Programs
  5. Hemispherx Biopharma Announces $5.3 Million in Expected Gross Proceeds from Recently Expired Rights Offering
  6. Hemispherx Announces Dutch Health Inspectorate Approval to Extend the Ampligen Pancreatic Cancer Early Access Program Until March 2020
  7. Hemispherx Biopharma Announces Extension of Rights Offering Period to March 5, 2019
  8. Hemispherx Biopharma Updates the Terms of Previously Announced Rights Offering and Announces Senior Management and Directors All Plan to Participate in the Offering  
  9. Hemispherx Biopharma Announces Commencement of Rights Offering Subscription Period
  10. Hemispherx Biopharma Reminds Investors of Today’s Deadline to be a Stockholder of Record
  11. Hemispherx Biopharma Announces Commencement of a New 45 Subject Clinical Trial Combining Ampligen and Merck’s Keytruda in the Treatment of Recurrent Ovarian Cancer
  12. Hemispherx Biopharma Announces Key Dates and Timeline for Stockholder Participation in Rights Offering
  13. Hemispherx Biopharma Shares CEO’s Presentation at the NobleConXV Conference
  14. Recent Analysis Shows The Chemours, Inter Parfums, Newmont Mining, Sanderson Farms, NGL Energy Partners LP, and Hemispherx BioPharma Market Influences — Renewed Outlook, Key Drivers of Growth
  15. REPEAT - Hemispherx Biopharma’s CEO to Present at the 15th Annual NobleConXV Conference
  16. Hemispherx Biopharma’s CEO to Present at the 15th Annual NobleConXV Conference
  17. Hemispherx Biopharma Announces IRB Approval of Clinical Study in Metastatic Triple Negative Breast Cancer in Collaboration with Roswell Park Comprehensive Cancer Center
  18. Hemispherx Biopharma Inc. Announces Advancement in Expanded Access Program for Ampligen in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
  19. Hemispherx Biopharma Issues Business Update to Clarify Apple iOS12 Stocks Application ‘No Recent Stories’ Misinformation
  20. Hemispherx Biopharma Inc. Announces First Large Ampligen Shipment to a Clinical Site for Use in U.S. Expanded Access Program